Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bayer and Onyx Pharmaceuticals (ONXX) announced Monday morning that a Phase III study of lung cancer treatment Nexavar did not meet its primary endpoint -- improving overall survival. The two pharmaceutical firms said they were "disappointed" with the failure of the trial and that they will evaluate the findings to see if the data may have any impact on other Nexavar trials. This trial was measuring Nexavar plus the standard treatment chemotherapy drugs against the chemo drugs alone in patients with newly diagnosed non-small cell lung cancer. Non-small cell lung cancer comprises roughly 85% to 90% of diagnosed lung cancers. Nexavar is already used to treat kidney and liver cancer.
Onyx Pharma
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
